These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias. Sung RJ; Juma Z; Saksena S Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Atkinson AJ; Ruo TI; Piergies AA Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345 [TBL] [Abstract][Full Text] [Related]
6. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Kosoglou T; Rocci ML; Vlasses PH Clin Pharmacol Ther; 1988 Oct; 44(4):467-77. PubMed ID: 2458879 [TBL] [Abstract][Full Text] [Related]
7. Torsade de pointes induced by N-acetylprocainamide. Chow MJ; Piergies AA; Bowsher DJ; Murphy JJ; Kushner W; Ruo TI; Asada A; Talano JV; Atkinson AJ J Am Coll Cardiol; 1984 Sep; 4(3):621-4. PubMed ID: 6206104 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570 [TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Winkle RA; Jaillon P; Kates RE; Peters F Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. Ellis EJ; Ravis WR; Malloy M; Duran SH; Smyth BG J Vet Pharmacol Ther; 1994 Aug; 17(4):265-70. PubMed ID: 7525982 [TBL] [Abstract][Full Text] [Related]
14. [Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. Liu XQ; Huang SK Zhongguo Yao Li Xue Bao; 1991 Jan; 12(1):7-11. PubMed ID: 1719744 [TBL] [Abstract][Full Text] [Related]
15. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472 [TBL] [Abstract][Full Text] [Related]
16. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide. Sonnhag C; Karlsson E Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673 [TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects of N-acetylprocainamide in human beings. Jaillon P; Rubenson D; Peters F; Mason JW; Winkle RA Am J Cardiol; 1981 May; 47(5):1134-40. PubMed ID: 6164285 [TBL] [Abstract][Full Text] [Related]